TIM S.A. and Summit Therapeutics hit new 52-week lows

The provided articles detail separate market movements for TIM S.A. and Summit Therapeutics PLC, both of which reached new 52-week lows during recent trading sessions.

TIM S.A. shares traded as low as $17.14, with a market capitalization of $8.42 billion. While some analysts, such as Wall Street Zen, have upgraded the stock, others like Barclays have lowered price objectives. The company reported quarterly earnings of $0.42 per share on June 17th.

Summit Therapeutics PLC shares hit a 52-week low of $12.15. Despite the price drop, several analysts maintain buy or overweight ratings, though target prices have been adjusted by firms like Guggenheim and Stifel Nicolaus. The company reported a quarterly loss of $0.28 per share, slightly missing consensus estimates.